Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade

Table 2

The clinical factors in the responders and nonresponders to second-line CAB therapy.

	Responders (50% PSA change)	Nonresponders	value
Number of patients (%)	8 (40%)	12 (60%)	—
Clinical stage, (%)
T2	1 (12.5)	0 (0)
T3	5 (62.5)	6 (50)
T4	2 (25.0)	6 (50)	0.25
Gleason score, (%)
6	1 (12.5)	0 (0.0)
7	1 (12.5)	2 (16.7)
8	2 (25.0)	2 (16.7)
9	4 (50.0)	7 (58.4)
10	0 (0)	1 (8.3)	0.654
Mean PSA at the diagnosis, ng/mL (range)	487.5 (23.8–2350)	941 (17.2–5740)	0.94
Mean nadir PSA after first-line CAB therapy, ng/mL (range)	2.06 (0.003–14.7)	2.67 (0.011–16.8)	0.11
Mean duration to nadir PSA after first-line CAB, months	12.3 (3–26)	13.8 (2–48)	0.64
Mean duration of first-line CAB therapy, months	23 (11–38)	18.4 (7–50)	0.32
Mean PSA at the start of second-line CAB therapy, ng/mL (range)	4.88 (0.116–20.7)	24.8 (0.114–116.3)	0.09
Mean duration of the response to second-line CAB therapy, months	18.4 (3–26)	—	—
AWS	0	1	—

CAB: combined androgen blockade; AWS: antiandrogen withdrawal syndrome.